Compare Chewy Inc (CHWY) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chewy Inc vs BIO-TECHNE Corp — how do they compare? Chewy Inc trades at $22.48 (market cap $9.25B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Chewy Inc pays none. Which is the better fit depends on your goals.
| CHWY | TECH | |
|---|---|---|
Market Cap | $9.25B | $11.24B |
Sector | Consumer Cyclical | Health |
52-Week High | $42.33 | $72.29 |
52-Week Low | $17.51 | $43.31 |
Enterprise Value | $9.21B | $11.32B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chewy (CHWY) trades at $23.53, up 0.43% with a bullish technical signal supported by moving averages. The company shows strong revenue growth from $8.9B in 2022 to $11.86B in 2025, with net income turning positive at $393M. Recent earnings beat expectations in Q1 2026 with EPS of $0.43 versus $0.24 expected. Analyst consensus remains strongly bullish with 81.58% buy ratings and a $33.82 price target, representing 44% upside potential from current levels.
Chewy's outlook appears favorable with expanding veterinary services and Autoship subscription model driving recurring revenue. Key risks include competitive pressure from Amazon and Walmart, insider selling activity, and margin compression as net income margin is projected to decline to 1.98% in 2026. The stock offers growth potential but requires monitoring of execution against aggressive expansion plans.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Chewy Inc
Chewy is the largest e-commerce pet care retailer in the U.S., generating $8.9 billion in 2021 sales across pet food, treats, hard goods, and pharmacy categories. The firm was founded in 2011, acquired by PetSmart in 2017, and tapped public markets as a standalone company in 2019, after spending a couple of years developing under the aegis of the pet superstore chain. The firm generates sales from pet food, treats, over-the-counter medications, medical prescription fulfillment, and hard goods, like crates, leashes, and bowls.
Read more on CHWY →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
